Marinus Pharmaceuticals Gets FDA Approval for Ztalmy

Marinus Pharmaceuticals said the FDA has approved Ztalmy oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.

• It is expected to be available through a designated specialty pharmacy in July 2022

To view the source of this information, click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used with permission.